AERI Aerie Pharmaceuticals Inc.

38.22
-0.79  -2%
Previous Close 39.01
Open 39
Price To Book 6.47
Market Cap 1737237165
Shares 45,453,615
Volume 476,464
Short Ratio
Av. Daily Volume 591,938

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 181210369
  2. 8-K - Current report 181174879
  3. S-8 - Securities to be offered to employees in employee benefit plans 181166736
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166378
  5. 8-K - Current report 181162971

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date March 14, 2019.
Roclatan
Glaucoma
PDUFA date February 28, 2018. Approved ahead of schedule - December 18, 2017.
Rhopressa
Glaucoma

Latest News

  1. See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
  2. Aerie Division's Prospects Have Analysts Bullish On American Eagle
  3. Hedge Funds Are Selling Aerie Pharmaceuticals Inc (AERI)
  4. Should You Get Rid of Aerie Pharmaceuticals (AERI) Now?
  5. Investor Expectations to Drive Momentum within Mirati Therapeutics, comScore, Nuance Communications, Carnival, Aerie Pharmaceuticals, and TrueCar — Discovering Underlying Factors of Influence
  6. Mariko Gordon's Top 5 New Buys
  7. Aerie Pharmaceuticals (AERI): Moving Average Crossover Alert
  8. Aerie (AERI) Q3 Earnings Miss, Rhopressa Gains Traction
  9. Aerie Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
  10. Edited Transcript of AERI earnings conference call or presentation 6-Nov-18 10:00pm GMT
  11. Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates
  12. Aerie: 3Q Earnings Snapshot
  13. Aerie Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
  14. Aerie Pharmaceuticals to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 6, 2018
  15. Aerie completes Durham HQ expansion
  16. Aerie Pharmaceuticals Establishes GMP PRINT® Production Facility in an Expanded Global Headquarters

SEC Filings

  1. CT ORDER - Confidential treatment order 181210369
  2. 8-K - Current report 181174879
  3. S-8 - Securities to be offered to employees in employee benefit plans 181166736
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166378
  5. 8-K - Current report 181162971
  6. 8-K - Current report 181133217
  7. 8-K - Current report 181123511
  8. 8-K - Current report 181112118
  9. 8-K - Current report 181099288
  10. 8-K - Current report 181077787